关键词: 索拉非尼, p?ERK, SH3GL1, 原发性肝癌, 耐药

Abstract:

 Objective To evaluate the expression of SH3GL1 and p?ERK in hepatocellularcarci-mona（HCC） and their correlation with the clinical characteristics and their impact on the efficacy of sorafenib therapy. Methods The specimens of the patients who underwent surgical resection due to HCC in Sun Yat?sen Memorial Hospital and then received sorafenib therapy after the surgery were collected from January 2008 to December 2016. Immunohistochemical staining（IHC）was used to analyze the expression of SH3GL1 and p?ERK in these tissues. The information of the patients included the gender, age, status of HBsAg, AFP value, Child-Pugh stage of liver function, ECOG performance status before surgery, tumor differentiation degree, vascular invasion, extrahepatic metastasis, tumor number and tumor staging was divided into different groups. Further, the correlations between the IHC scores and the clinical factors and the prognosis of patients were analyzed. Results The positive rate of SH3GL1 and p-ERK in HCC samples were high, and there was positive correlation between these two proteins（P<0.001）. The strong expression of SH3GL1 was correlated with extrahepatic metastasis, multiple tumor and tumor staging while the strong expression of p?ERK was correlated with tumor staging. The risk factors that worsened the prognosis of HCC patients who received sorafenib treatment after surgical resection included age less than50 years old, strong expression of SH3GL1, strong expression of p-ERK, existence of extrahepatic metastasis and multiple tumor. Further, strong expression of SH3GL1, existence of extrahepatic metastasis and multiple tumor were the independent risk factor. Conclusion The expression of SH3GL1 and p-ERK were correlated with several tumor characteristics of HCC and the prognosis of patients, and high expression of these two proteins are risk factor for patients overall survival.

Key words: hepatocellular carcinoma, sorafenib, SH3GL1, drug resistance, p?ERK